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OlRONOPHARMACOLOGY OF MITQXANIRONE (MX): EVIDENCE 
FOR A CIRCADIAN RHYTIlM OE ITS MYELQTOXICITY FROM AN 
ANlMAL MODEL AND A CLrNICAL PILOT TRIAL 
M Halle!; F l .tyj° I l.an~nma)'er.1. Kam!DC!IJltier. aod. B Emmericb 
Thc dosing time of anticancu agcnts largely affects botb the tolerance and 
Ihr: antineoriastic activity of cytostatic drugs. Considcnr.blc circadian 
variations 0 thcsc drug cffects have been reported foT anthracylines such as 
daunorubicin. doxorubicin, epirubicin and 4'-(}.teuahydropyranyladria-
mycin. This lcd us 10 investigatc tbc chronopharmacolopc propcrtlcs of 
MX, an anlhraquinone with similar properties. Ouf invesligatiolls were 
conducted in an animal modcl an<! a clinical pilot study. 144 86D2Fl mice 
wruch were synchronized by standardized 12h:12h ligbt-darkness cyc1es, 
were iojectcd a single, potcntially lethal Lv. dose of MX (13, 14.5.or 16 
mglkg) 31 six diff~nllime points (8 animals per time point). All mice 
rtteiving 13 or 14.5111f1kg MX s~ived. ifthc: dnIg bad been injcctc:d at 3, 
7. 11 , or 19 haUD aftet light on (HALO). but 2S':l died if Ihe same doses 
bad bccn given BI 23 HALO. The administration of 16 mg/k& MX at 3 ur 7 
HALO respectivdy killcd !()()'J, or 80% of nUce. as cornparW to 1I0flC (!) 
following drug dos;ng at 11 or IS HALO (Xl .. 40; p<O.OOI). In 
subscquent experiments, 99 86D2Fl mice were injected 14.5 mglkg at four 
different time points, and the body weight, WBC, or spleen wcight wcre 
determined as compan:d 10 baseline levels after S,9, 14 or 21 days. 00 d 
5, leukopenia varied from -84% at 4 HALO 10 -34% at 22 HALO, and 
spleen weightloss varied from -34% (22 HALO) CO -83% (14 HALO) 
(1'<0.01). On d 9, wherc the maximal body weightloss oc:cured, !his 
variable was least at 16 HALO (-28%), as cornpared 10 -36% at 22 HALO 
(1)<0.01) . We then conducted a clinical pilot srudy in 9 cancer patients 
receiving a combination chemoihentpy with MX (8 mgJm2/d IV. d 1+2) and 
prednimustin (pM; 100 mg/m2/d PO, d 1-5). Whi le PM was I;oostantly 
given at 8hOO, the dosing time of MX was I;hanged aftcr each treatment 
course in eoch yatient (2hOO, 6hOO, IQhOO, 14hOO, 18Il00, 22hOO). Agam, 
a small, 001 significant circadian variation of the leukocyte nadirs was 
observed wi lh highest I;ounts al 22hOO and lowest counts al 6hOO 
(differeoce 20%; P4J.OS; Wilcoxon). Taken lOgether, both preclinical and 
dinical data suggest thal the toxj{:jty ofMX may be signifl(;ll/\tly reduced by 
com:ctcircadian timing of ilS administration. MX seems CO be best IOlcrated 
in the second half of the activity span. 
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